Genfit share price declines following its results
The Lille-based biotech company specializing in hepatic and metabolic diseases extends its decline this Tuesday, following the publication of its first-half 2026 results. Despite solid cash reserves and royalties in sharp progression, the market penalizes the deterioration in net income. The stock ranks among the steepest declines on the SBF 120 at midday.
Iqirvo royalties triple, but net loss widens to 26.1 million euros
Published on September 28, 2026, Genfit's half-year accounts present a contrasting picture. Royalties from Iqirvo, the primary biliary cholangitis treatment marketed by Ipsen, have tripled to reach 21 million euros. Cash reserves remain comfortable at 113.8 million euros, giving the company appreciable operational visibility.
However, net loss widened to 26.1 million euros compared to 10.0 million a year earlier, due to the combined effect of revenue structure and higher financial charges. It is this deterioration in the bottom line that is weighing on the share price during the session. According to the consensus of analysts surveyed, the stock is currently trading at around 50 times the earnings of the current fiscal year, a high multiple that reflects expectations placed on the pipeline, but which leaves little room in case of disappointment on results.
A technical configuration under pressure, with a support level at 8.92 euros in sight
Genfit declines 2.03% to 9.64 euros during the session, continuing a monthly decline of nearly 33%. The stock is trading well below its 20-day moving average (12.04 euros, a gap of nearly 20%) and its 50-day moving average (13.10 euros, a gap exceeding 26%), two averages that reflect the scale of the correction underway since mid-September. Only the 200-day moving average at 9.45 euros remains slightly below the current price, constituting the last long-term reference still favourable. The RSI at 33 is in a near-oversold zone, without having reached the extreme levels of last week.
If the decline were to accelerate, the support level at 8.92 euros represents the next threshold to monitor. Furthermore, according to the statements consulted, two funds combine 1.10% of the capital sold short, a position that has increased by 1.10 percentage points over thirty days. This rapid rise in the bearish bet testifies to institutional pressure on the stock, although the absolute level remains moderate.
